Skip to content
Latest news
CinDome Pharma Announces First Patient Dosed in the envisionGI Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis
Home
About
Portfolio
Pipeline
News
Contact
Home
About
Portfolio
Pipeline
News
Contact
Our portfolio companies have the potential for transformational change in the way a disease area is treated and significantly improves the patient quality of life.
LEARN MORE
LEARN MORE
LEARN MORE
INVESTOR INQUIRIES
Send Message
CAREER INQUIRIES
Send Message
GENERAL INQUIRIES
Send Message